Paloma Partners Management Co bought a new stake in Haemonetics Co. (NYSE:HAE) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 13,803 shares of the medical instruments supplier’s stock, valued at approximately $1,582,000.
Other institutional investors have also made changes to their positions in the company. Chicago Equity Partners LLC raised its stake in Haemonetics by 34.0% in the second quarter. Chicago Equity Partners LLC now owns 86,665 shares of the medical instruments supplier’s stock valued at $7,772,000 after purchasing an additional 22,000 shares in the last quarter. Liberty Mutual Group Asset Management Inc. acquired a new position in Haemonetics in the second quarter valued at about $932,000. ING Groep NV acquired a new position in Haemonetics in the second quarter valued at about $485,000. MetLife Investment Advisors LLC raised its stake in Haemonetics by 142.0% in the second quarter. MetLife Investment Advisors LLC now owns 57,955 shares of the medical instruments supplier’s stock valued at $5,197,000 after purchasing an additional 34,009 shares in the last quarter. Finally, American Century Companies Inc. raised its stake in Haemonetics by 231.1% in the third quarter. American Century Companies Inc. now owns 1,005,784 shares of the medical instruments supplier’s stock valued at $115,243,000 after purchasing an additional 701,976 shares in the last quarter. 97.58% of the stock is owned by institutional investors.
HAE stock opened at $102.85 on Friday. The stock has a market capitalization of $5.32 billion, a P/E ratio of 46.75, a P/E/G ratio of 3.53 and a beta of 1.09. Haemonetics Co. has a 52 week low of $57.31 and a 52 week high of $117.56. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.92 and a quick ratio of 2.06.
HAE has been the subject of a number of analyst reports. Zacks Investment Research raised Haemonetics from a “hold” rating to a “strong-buy” rating and set a $122.00 price target for the company in a research note on Friday, October 12th. Barrington Research reaffirmed a “buy” rating and issued a $127.00 price target on shares of Haemonetics in a research note on Friday, October 5th. Finally, TheStreet downgraded Haemonetics from a “b” rating to a “c+” rating in a research note on Monday, August 20th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and two have assigned a strong buy rating to the stock. Haemonetics currently has an average rating of “Buy” and a consensus target price of $113.20.
In other Haemonetics news, CFO William P. Mr. Burke sold 841 shares of the business’s stock in a transaction dated Thursday, October 25th. The stock was sold at an average price of $46.76, for a total transaction of $39,325.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Dan Goldstein sold 1,693 shares of the business’s stock in a transaction dated Monday, December 10th. The stock was sold at an average price of $102.91, for a total value of $174,226.63. The disclosure for this sale can be found here. In the last three months, insiders have sold 60,483 shares of company stock valued at $6,706,043. Insiders own 1.04% of the company’s stock.
WARNING: This report was reported by BBNS and is the property of of BBNS. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://baseballnewssource.com/2018/12/16/paloma-partners-management-co-invests-1-58-million-in-haemonetics-co-hae/3084873.html.
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
See Also: Google Finance Portfolio Workaround
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.